Bradley, A S, Ford, B, Bansal, A S · Clinical and experimental immunology · 2013 · DOI
This study looked at different types of B cells (immune cells that help fight infection) in people with ME/CFS compared to healthy people. Researchers found that ME/CFS patients had more immature B cells and fewer fully developed B cells than healthy controls, suggesting their immune system might not be developing B cells normally. This finding is interesting because a drug that removes B cells helped some ME/CFS patients improve.
This is one of the first studies to identify objective differences in B cell populations in ME/CFS patients, providing potential biological support for immune system abnormalities in this condition. The findings offer a mechanistic basis for investigating why B cell-targeted therapies like Rituximab have shown clinical benefit in some ME/CFS patients, and could guide future diagnostic or therapeutic approaches.
This study does not prove that B cell abnormalities cause ME/CFS, only that they are associated with the condition—the direction of causality is unclear. It does not explain the function of these B cells or whether the detected changes are sufficient to account for ME/CFS symptoms. The study also cannot determine whether these changes are primary immune defects or secondary consequences of the disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →